At a Glance:
- Risk Return Analysis (RRA) model quantifying current risk exposure
- Specific dollar values for FDA enforcement, recall costs, market share loss
- Connectivity roadmap showing incremental security investments
- Prioritized initiatives by ROI, timeline, and regulatory alignment
Risk Return Analysis Model:
Medcrypt deployed its Risk Return Analysis (RRA) model to quantify the manufacturer's current risk exposure across regulatory, reputational, and financial dimensions. The analysis revealed specific dollar values associated with potential FDA enforcement actions, recall costs, and market share loss from security incidents.
Strategic Connectivity Roadmap:
Beyond quantifying risk, Medcrypt developed a practical connectivity roadmap showing how incremental security investments would reduce exposure while enabling new revenue opportunities through connected device capabilities. The roadmap prioritized initiatives by ROI, timeline, and regulatory alignment, providing executives with clear decision criteria for both existing device hardening and next-generation secure-by-design development.